Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 24, 2012Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions
Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Emerge™ PTCA[1] Dilatation Catheter. The Emerge...
-
Apr 23, 2012REPRISE I Trial Results to be Presented at EuroPCR 2012
Boston Scientific Corporation (NYSE: BSX) announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate...
-
Apr 19, 2012
Boston Scientific Corporation (NYSE: BSX) announces financial results for the first quarter ended March 31, 2012, as well as sales and earnings per...
-
Apr 11, 2012
Boston Scientific Corporation (NYSE: BSX) announces the U.S. market launch of its Z Flex-270™ Steerable Sheath. The device is intended for use in...
-
Apr 10, 2012
Boston Scientific Corporation (NYSE: BSX) announces it will webcast its first-quarter 2012 financial results conference call on Thursday, April 19, at...
-
Apr 10, 2012Advanced devices designed to treat chronotropic incompetence, which affects up to 42 percent of pacemaker patients
Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval and European market launch of its INGENIO™ and ADVANTIO™ pacemakers and...
-
Apr 2, 2012
Boston Scientific Corporation (NYSE: BSX) announces the launch of its BackStop® Gel, a new technology designed to prevent stone migration during...
-
Mar 27, 2012CTAF report supports safety, efficacy and positive health outcomes of bronchial thermoplasty for treatment of patients with severe asthma
Boston Scientific Corporation (NYSE: BSX) announces the first published technology assessment in support of the safety, efficacy and long-term...
-
Mar 26, 2012HORIZONS II AMI trial to enroll up to 10,000 patients worldwide, making it the largest randomized trial to study coronary stents in heart attack patients
Boston Scientific Corporation (NYSE: BSX) announces its support of the HORIZONS II AMI clinical trial, which is designed to evaluate the...
-
Mar 25, 2012
Boston Scientific Corporation (NYSE: BSX) announces two-year follow-up data from the pivotal PLATINUM Workhorse trial comparing the...
-
Mar 25, 2012Quantitative Coronary Angiographic outcomes from PERSEUS and PLATINUM clinical trials presented at ACC 2012
Boston Scientific Corporation (NYSE: BSX) announces results from a quantitative coronary angiographic (QCA) analysis of the incidence of...
-
Mar 22, 2012Company's WallFlex Biliary Stents now available with a Transhepatic delivery system for use by interventional radiologists in treating obstructions within the biliary tract
Boston Scientific Corporation (NYSE: BSX) announces the U.S. and international launch of the WallFlex® Biliary Transhepatic Stent System. This...
-
Mar 20, 2012
Boston Scientific Corporation (NYSE: BSX) releases its schedule of product-related clinical research at the 61th Annual Scientific Session of the...
-
Mar 19, 2012Priority Health and HealthPartners issue new medical policies to cover catheter-based procedure shown to provide long-lasting control of severe asthma
Boston Scientific Corporation (NYSE: BSX) welcomes a milestone in private insurance reimbursement coverage for bronchial thermoplasty (BT) performed...
-
Mar 15, 2012Radiofrequency ablation catheter designed to treat a variety of arrhythmias
Natick, MA (March 15, 2012) -- Boston Scientific Corporation (NYSE: BSX) today announced Health Canada approval of the Blazer™ Open-Irrigated Catheter, the Company’s latest radiofrequency...
-
Mar 8, 2012Company gains first and only commercially available subcutaneous ICD technology to offer lifesaving therapy to patients at risk of sudden cardiac arrest
Boston Scientific Corporation (NYSE: BSX) announces the exercise of its option to acquire Cameron Health, Inc., a privately held company based in San...
-
Mar 8, 2012
Boston Scientific Corporation (NYSE: BSX) and Lumenis, the market leader in holmium laser technology, announced the signing of a five-year contract...
-
Mar 1, 2012Next-generation coronary stent employs innovative alloy designed to improve acute performance
Boston Scientific Corporation (NYSE: BSX) announces the launch of the PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System in...
-
Feb 23, 2012
Boston Scientific Corporation (NYSE: BSX) announces the first implants of a TELIGEN® implantable cardioverter defibrillator (ICD) in China. The...
-
Feb 22, 2012ION™ and TAXUS® Liberte® Paclitaxel-Eluting Stent Systems now approved for treating patients with acute myocardial infarction in the U.S.
Boston Scientific Corporation's (NYSE: BSX) ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS® Liberte® Paclitaxel-Eluting...
-
Feb 22, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2012 RBC Capital Markets' Global Healthcare Conference on February 29 in...
-
Feb 13, 2012
Boston Scientific Corporation (NYSE: BSX) announces that Moody's Investors Service has upgraded the Company's corporate credit rating to an investment...
-
Feb 8, 2012TruePath™ CTO Device designed to facilitate crossing of chronic total occlusions
Boston Scientific Corporation (NYSE: BSX) announces the U.S. launch of the TruePath™ CTO Device, designed to facilitate the crossing of chronic total...
-
Feb 7, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Leerink Swann 2012 Global Healthcare Conference on February 15 in New York....
-
Feb 7, 2012Studies published in peer-reviewed medical journals
Boston Scientific Corporation (NYSE: BSX) welcomes positive results from three studies of the WallFlex® Enteral Stent Systems, a family of...
-
Feb 6, 2012Boston Scientific Announces Global Launch of Expect™ 19 Flex Endoscopic Ultrasound Aspiration NeedleNew device offers excellent flexibility and large size for acquiring tissue samples
Boston Scientific Corporation (NYSE: BSX) announces the global launch of the Expect 19 Flex Endoscopic Ultrasound Aspiration Needle, used for acquiring...
-
Feb 3, 2012
Paris, France and Miami Beach, FL (February 3, 2012) – Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval of the Infinion™ 16 Percutaneous Lead for its Precision Plus™...
-
Feb 2, 2012
Boston Scientific Corporation (NYSE: BSX) announces financial results for the fourth quarter and full year ended December 31, 2011, as well as sales and...
-
Feb 1, 2012Platinum chromium coronary stent with enhanced delivery system now available in Europe and other international countries
Boston Scientific Corporation (NYSE: BSX) announces first patient use and European market launch of the PROMUS Element™ Plus Everolimus-Eluting...
-
Jan 31, 2012
Singapore (January 31, 2012) – Boston Scientific Corporation (NYSE: BSX) announces the creation of its Asia-Pacific regional organization that includes Australia, New Zealand, China, Hong Kong,...
-
Jan 26, 2012NICE Report Supports Safety and Effectiveness of Alair® System
London (January 26, 2012) -- Boston Scientific (UK) welcomes new guidance from the National Institute for Health and Clinical Excellence (NICE) on the use of Bronchial Thermoplasty (BT) to treat...
-
Jan 23, 2012Johnson and Johnson's patents found invalid
Boston Scientific Corporation (NYSE: BSX) announces that the U.S. District Court for the District of New Jersey has found all the asserted patents in...
-
Jan 20, 2012
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended...
-
Jan 16, 2012Nine-month data presented at ISET support safety and efficacy of Epic Stent in iliac stenting
Boston Scientific Corporation (NYSE: BSX) reports nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes...
-
Jan 4, 2012Boston Scientific's Alair® Bronchial Thermoplasty System Achieves Important Reimbursement MilestonesCMS pass-through payment and new CPT®[1] codes established for catheter-based procedure to treat severe asthma
Boston Scientific Corporation (NYSE: BSX) announced that the Centers for Medicare and Medicaid Services (CMS), the agency that administers the Medicare...
-
Jan 3, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. Hank...
-
Dec 12, 2011
Boston Scientific Corporation (NYSE: BSX) announces the U.S. launch of its Charger™ PTA Balloon Catheter, a 0.035" percutaneous transluminal...
-
Dec 8, 2011World's first and only 16-contact percutaneous lead provides innovative, new option for physicians to treat chronic pain
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous...
-
Nov 30, 2011Extended ICD/CRT-D program offers warranties up to 10 years
Boston Scientific Corporation (NYSE: BSX) announced that, along with today's introduction of a new family of INCEPTA™ and ENERGEN™ implantable...
-
Nov 30, 2011New family of cardiac devices offers excellent longevity and industry's longest warranty
Boston Scientific Corporation (NYSE: BSX) announces FDA approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy...
-
Nov 22, 2011Approval marks transition to internally manufactured everolimus-eluting stent in the U.S.
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting...
-
Nov 18, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray 23rd Annual Healthcare Conference on November 30 in New...
-
Nov 16, 2011Innovative left atrial appendage closure device offers proven alternative to anticoagulant drugs for patients in atrial fibrillation at high risk for stroke
Boston Scientific Corporation's (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA) Closure Device has been implanted in the first patients in Latin...
-
Nov 15, 2011
Boston Scientific Corporation (NYSE: BSX) commends the leadership of Senator Al Franken (D-MN), Senator Lamar Alexander (R-TN) and Senator John Kerry...
-
Nov 11, 2011Positive results from COBRA trial presented at TCT
Boston Scientific Corporation (NYSE: BSX) welcomed positive outcomes from the COBRA clinical trial, which evaluated post-dilation of...
-
Nov 11, 2011EVOLVE trial evaluates fourth-generation everolimus-eluting coronary stent with ultra-thin abluminal bioabsorbable polymer
Boston Scientific Corporation (NYSE: BSX) reports results from the EVOLVE First Human Use trial demonstrating the non-inferiority of...
-
Nov 8, 2011
Boston Scientific Corporation (NYSE: BSX) reports positive outcomes from the CABANA post-approval study of the Carotid WALLSTENT®...
-
Nov 8, 2011PLATINUM Long Lesion clinical results presented at TCT show no cardiac death, heart attack or stent thrombosis at one year
Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating excellent...
-
Nov 8, 2011Long-term results presented from two studies evaluating advanced paclitaxel-eluting stent
Boston Scientific Corporation (NYSE: BSX) reports positive long-term data from the PERSEUS clinical program, which demonstrated...
-
Nov 2, 2011Multi-center study published in Gastrointestinal Endoscopy is largest ever reported on peroral cholangioscopy
Boston Scientific Corporation (NYSE: BSX) welcomes study results published in the October issue of Gastrointestinal Endoscopy showing an overall...